Itramax 200 Capsule contains Fluconazole 200 mg, a triazole antifungal agent indicated for the treatment of various fungal infections. Fluconazole acts by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase, thereby disrupting the synthesis of ergosterol, an essential component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itramax 200 is commonly prescribed for oropharyngeal and esophageal candidiasis, systemic candidiasis, cryptococcal meningitis, and other susceptible fungal infections. The capsule formulation allows for convenient oral administration with good bioavailability, ensuring effective plasma concentrations. Fluconazole is generally well-tolerated; however, potential side effects include gastrointestinal disturbances such as nausea, abdominal pain, and diarrhea, as well as headache and rash. Caution is advised in patients with hepatic impairment or those receiving concomitant medications metabolized by the cytochrome P450 system due to possible drug interactions. Dosage and duration of therapy should be tailored according to the type and severity of infection, patient response, and clinical judgment. Itramax 200 Capsule should be used under medical supervision to ensure optimal efficacy and safety in the management of fungal infections.